关注肝肾综合征研究新进展

Concerns for the recent progression of hepatorenal syndrome

肝肾综合征(hepatorenal syndrome,HRS)是由严重肝脏疾病引起的一种以肾功能衰竭为特征的并发症。HRS的发病机制是有效血容量不足和内脏血管活性物质失衡导致肾内血管收缩。HRS的预后非常差,其出现往往预示肝病进入终末期。近年来,血管收缩剂、经颈静脉肝内门体分流和肝移植等治疗方法已应用于HRS。本文将就HRS的发病率、发病机制、诊断和治疗方面的新进展作一评价。

Hepatorenal syndrome （HRS） is a clinical condition that frequently occurs in patients with advanced liver disease and portal hypertension, which is characterized by impaired renal function. The pathophysiological mechanisms of HRS are marked abnormalities in the arterial circulation and activity of the endogenous vasoactive systems. The prognosis of HRS is extremely poor. In recent years, three mainly different therapeutic methods, including pharmacological treatment, transjugular intrahepatic portosystemic shunt （TIPS） , liver transplantation, have been established for the treatment of HRS, but liver transplantation is the only therapy that radically improves the prognosis of HRS. The purpose of the present paper is to provide a review of the pathophysiology, diagnosis, and current and emerging therapies on HRS.